Novartis AG CEO Vas Narasimhan feels the firm's pipeline is underappreciated by the markets and as well as talking up late and mid-stage candidates, he has highlighted earlier high-risk, high-reward projects to the investment community.
At a virtual Meet Novartis Management event, Narasimhan decided to dedicate a slice of his presentation to five "wild cards."...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)